Genix Pharmaceuticals Corporation Genix Pharmaceuticals Corporation

Genix Pharmaceuticals Corporation

GENPF

Rank in Stocks #33269
Genix Pharmaceuticals Corporation, established in 1993 and headquartered in... Genix Pharmaceuticals Corporation, established in 1993 and headquartered in Vancouver, Canada, is actively involved in the creation, production, licensing, and distribution of various life science products. The company's primary focus in the Canadian market is on nutraceuticals and pharmaceuticals. Their product pipeline features several key developments: Flu-X: An herbal treatment available as an oral solution or spray, targeting viral infections, influenza, and coronaviruses responsible for common colds. Renochlor: A nutritional supplement formulated to support the revitalization and maintenance of kidney health and function. Sucanon: An insulin sensitizer designed to reduce blood sugar by improving the sensitivity of muscle, fat, and liver cells to insulin. Beyond these, Genix Pharmaceuticals also offers a wide range of other nutraceuticals and pharmaceutical items. This selection includes supplements such as bee propolis capsules, liquid calcium softgels, seal oil softgels, marine lipid softgels, lecithin softgels, fish oil softgels, EPO softgels, and spirulina powder, alongside ophthalmic products like eye ointments and drops. The company operated under the name Alta Natural Herbs & Supplements Ltd. until it adopted its current identity, Genix Pharmaceuticals Corporation, in June 2019.
Share Price
$0.0104
Last synced: 2026-11-10
Market Cap
$636.73K
Change (1 day)
0.00%
Change (1 year)
-70.89%
Country

Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this

Trade Genix Pharmaceuticals Corporation (GENPF)

Category

Healthcare
EPS for Genix Pharmaceuticals Corporation (GENPF)
EPS as of April 2026 TTM: $0.00
According to Genix Pharmaceuticals Corporation's latest financial reports, its current EPS (TTM) is $0.00. At the end of 2025 the company had an EPS of 0.00, equal to its 2024 EPS of 0.00.
EPS history for Genix Pharmaceuticals Corporation from 2000 to 2026
EPS at the end of each year
Year EPS Change
2026 (TTM) 0.00 344.44%
2025 0.00 344.44%
2024 0.00 -98.32%
2023 $-0.05 302.26%
2022 $-0.01 -40.89%
2021 $-0.02 108.33%
2020 $-0.01 227.27%
2019 0.00 -222.22%
2018 0.00 -154.00%
2017 $-0.01 100.00%
2016 0.00 -79.17%
2015 $-0.01 -1,433.33%
2014 0.00 -115.52%
2013 $-0.01 75.76%
2012 0.00 3,200.00%
2011 0.00 -98.63%
2010 $-0.01 143.33%
2009 0.00 233.33%
2008 0.00 -91.18%
2007 $-0.01 -38.18%
2006 $-0.02 -615.63%
2005 0.00 -260.00%
2004 0.00 17.65%
2003 0.00 -80.90%
2002 $-0.01 -49.72%
2001 $-0.02 40.48%
2000 $-0.01 0.00%
EPS for similar companies or competitors
Company EPS EPS Difference Country
$6.03 -223,429.63%
DE
$6.01 -222,611.11%
DE
$1.53 -56,874.07%
JP
$3.66 -135,655.56%
CH
$0.45 -16,766.67%
IL

Questions about Genix Pharmaceuticals Corporation's earnings per share (EPS)

What is Genix Pharmaceuticals Corporation's earnings per share (EPS)?

Genix Pharmaceuticals Corporation's earnings per share (EPS) over the last twelve months is $0.00, as of Apr 2026.

What was Genix Pharmaceuticals Corporation's earnings per share (EPS) in 2025?

In 2025, Genix Pharmaceuticals Corporation's earnings per share (EPS) was 0.00, compared with 0.00 in 2024.

How has Genix Pharmaceuticals Corporation's earnings per share (EPS) changed since 2020?

From 2020 to 2025, Genix Pharmaceuticals Corporation's earnings per share (EPS) was highest in 2025 (0.00) and lowest in 2023 ($-0.05).

How does Genix Pharmaceuticals Corporation's earnings per share (EPS) compare with similar companies?

Genix Pharmaceuticals Corporation's earnings per share (EPS) ($0.00) is lower than that of all 5 similar companies listed above. The highest among them is MERCK Kommanditgesellschaft auf Aktien, with $6.03.